A Year After a Scathing Attack By a Short Seller, Cellceutix Eyes the Nasdaq and Big Investors
A year after a scathing attack by an anonymous short seller thwarted plans to jump to the Nasdaq, Beverly biotech Cellceutix is hoping a new president with a big pharma background will jumpstart its transformation from a company that’s been mostly ignored by big investors.
into one that’s traded on the Nasdaq and has institutional shareholders.
into one that’s traded on the Nasdaq and has institutional shareholders.